Subscribe
pressmaster-shutterstock-com-3-1
Pressmaster / Shuterstock.com
5 May 2016Americas

AstraZeneca completes acquisition of Takeda’s respiratory business

AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Americas
FTC settles Hikma Roxane competition concerns
6 May 2016   The US Federal Trade Commission has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.
Americas
Allergan launches generic version of AstraZeneca cholesterol tablet
5 May 2016   Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Americas
FTC settles Hikma Roxane competition concerns
6 May 2016   The US Federal Trade Commission has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.
Americas
Allergan launches generic version of AstraZeneca cholesterol tablet
5 May 2016   Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

More on this story

Big Pharma
Genevant signs $600m liver fibrosis deal with Takeda
18 March 2021   Genevant Sciences has entered into a licence agreement for Takeda to develop and market a new liver fibrosis treatment.
Americas
FTC settles Hikma Roxane competition concerns
6 May 2016   The US Federal Trade Commission has approved a final order settling charges that pharmaceutical company Hikma’s buyout of Roxane Laboratories and Boehringer Ingelheim Roxane would be anticompetitive.
Americas
Allergan launches generic version of AstraZeneca cholesterol tablet
5 May 2016   Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB